415 related articles for article (PubMed ID: 32375873)
1. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
3.
Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.
Stewart T; Sossi V; Aasly JO; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Leverenz JB; Stoessl AJ; Wang Y; Ginghina C; Liu C; Cain KC; Auinger P; Kang UJ; Jensen PH; Shi M; Zhang J
Acta Neuropathol Commun; 2015 Jan; 3():7. PubMed ID: 25637461
[TBL] [Abstract][Full Text] [Related]
5. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
[TBL] [Abstract][Full Text] [Related]
6. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
7. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.
Aasly JO; Shi M; Sossi V; Stewart T; Johansen KK; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Kim HM; Leverenz JB; Ginghina C; Armaly J; Edwards KL; Snapinn KW; Stoessl AJ; Zhang J
Neurology; 2012 Jan; 78(1):55-61. PubMed ID: 22170881
[TBL] [Abstract][Full Text] [Related]
9. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?
Loeffler DA; Aasly JO; LeWitt PA; Coffey MP
J Parkinsons Dis; 2019; 9(3):467-488. PubMed ID: 31322581
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
11. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
12. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
Dzamko N; Rowe DB; Halliday GM
Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.
Ichinose H; Inoue KI; Arakawa S; Watanabe Y; Kurosaki H; Koshiba S; Hustad E; Takada M; Aasly JO
J Neural Transm (Vienna); 2018 Jan; 125(1):45-52. PubMed ID: 28864907
[TBL] [Abstract][Full Text] [Related]
14. Higher urate in LRRK2 mutation carriers resistant to Parkinson disease.
Bakshi R; Macklin EA; Logan R; Zorlu MM; Xia N; Crotty GF; Zhang E; Chen X; Ascherio A; Schwarzschild MA
Ann Neurol; 2019 Apr; 85(4):593-599. PubMed ID: 30761591
[TBL] [Abstract][Full Text] [Related]
15. Left corticospinal tract could be a biomarker to identify the dual prodromal LRRK2/GBA mutated Parkinson's disease.
Lin F; Ruan X; Zou X; Weng H; Zeng Y; Zheng J; Ye Q; Meng F; Chen X; Cai G
CNS Neurosci Ther; 2024 Jun; 30(6):e14728. PubMed ID: 38837664
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.
Aasly JO; Johansen KK; Brønstad G; Warø BJ; Majbour NK; Varghese S; Alzahmi F; Paleologou KE; Amer DA; Al-Hayani A; El-Agnaf OM
Front Aging Neurosci; 2014; 6():248. PubMed ID: 25309429
[TBL] [Abstract][Full Text] [Related]
17. CSF lamp2 concentrations are decreased in female Parkinson's disease patients with LRRK2 mutations.
Klaver AC; Coffey MP; Aasly JO; Loeffler DA
Brain Res; 2018 Mar; 1683():12-16. PubMed ID: 29456132
[TBL] [Abstract][Full Text] [Related]
18. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers.
Wang S; Liu Z; Ye T; Mabrouk OS; Maltbie T; Aasly J; West AB
Acta Neuropathol Commun; 2017 Nov; 5(1):86. PubMed ID: 29166931
[TBL] [Abstract][Full Text] [Related]
19. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D
Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease.
Podlesniy P; Vilas D; Taylor P; Shaw LM; Tolosa E; Trullas R
Neurobiol Dis; 2016 Oct; 94():10-7. PubMed ID: 27260835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
